Table 3 Bivariate analysis to determine variables associated with development of DNAemia ≥ 4000UI/ml
Variable | Total N = 113 | VL ≥ 4000 UI/ml N = 23 | VL < 4000 UI/ml N = 90 | OR (CI95%) | p |
|---|---|---|---|---|---|
Age | 52 (41–59) | 55 (39–62) | 51 (41–58) | 1.01 (0.97–1.06) | 0.34 |
Female sex | 57 (50%) | 13 (56%) | 44 (49%) | 1.35 (0.54.3.41) | 0.51 |
Hepatitis C | 23 (20%) | 3 (9%) | 10 (22%) | 0.52 (0.14–1.94) | 0.33 |
Cryptogenic cirrhosis | 24 (21%) | 3(13%) | 21 (23%) | 0.49 (0.13–1.82) | 0.28 |
Autoimmune hepatitis | 20 (18%) | 7 (30%) | 13 (14%) | 2.58 (0.89–7.51) | 0.08 |
Hepatocellular carcinoma | 25 (22%) | 5 (22%) | 20 (22%) | 0.97 (0.32–2.94) | 0.96 |
Child–Pugh C | 62 (55%) | 12 (52%) | 50 (55%) | 0.87 (0.34–2.18) | 0.77 |
MELD | 35 (31%) | 7 (30%) | 28 (31%) | 0.96 (0.35–2.61) | 0.95 |
Donor CMV IgG positive | 72/83 (87%) | 18/19 (95%) | 54/64 (84%) | 3.33 (0.39–27.87) | 0.26 |
Surgical time > 7 h | 27/109 (25%) | 4/22 (18%) | 23/87 (26%) | 0.61 (0.18–2.01) | 0.42 |
> 6 blood cell transfused | 24 (21%) | 5 (22%) | 19 (21%) | 1.03 (0.34–3.15) | 0.94 |
Reoperation | 10 (9%) | 1 (4%) | 9 (10%) | 0.4 (0.49–3.4) | 0.4 |
Grade 3 AKI | 25 (22%) | 4 (17%) | 21 (23%) | 0.69 (0.21–2.25) | 0.54 |
Posttransplant bacterial infection | 27 (24%) | 5 (22%) | 22 (24%) | 0.85 (0.28–2.58) | 0.78 |
Viral load growth rate > 0.16 UI/ml/day | 37/70 (53%) | 15/19 (79%) | 22/51 (43%) | 4.94 (1.43–16.98) | 0.011 |